Metastatic carcinoma of unknown primary (CUP) has a very poor prognosis. and no standard first-line therapy currently exists. Here. we report the results of a phase II study utilizing a combination of gemcitabine and irinotecan as first-line therapy. https://www.marcelovicente.com/product-category/q10-time-restore-treatment/